For Immediate Release
Chicago, IL – September 22, 2016 – Zacks Equity Research highlights Edwards Lifesciences (EW - Analyst Report) as the Bull of the Day and DaVita HealthCare Partners (DVA - Analyst Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysisCorcept Therapeutics Inc (CORT - Analyst Report) and CryoLife Inc (CRY - Snapshot Report) .
Here is a synopsis of all four stocks:
Bull of the Day :
The growth of Edwards Lifesciences (EW) into a $25 billion provider of cutting-edge heart surgery alternatives is an amazing success story of American ingenuity and medical business innovation.
I last wrote about the company as a Zacks #1 Rank stock in April when I owned it and shares leapt from $90 to new all-time highs above $105 on the company's latest data proving superiority, or at least equivalency, of its Sapien 3 valve replacement procedure to open heart surgery.
Pump Engineer Designs Cardiac Replacement Parts
It all began with the vision of the founder-inventor, a hydraulic engineer named Miles "Lowell" Edwards, who in 1958 set out to build the first artificial heart. By dialing down his dream a bit, was able to create an important life-saving industry. Here's the official story from the company website...
Edwards was a 60-year-old, recently retired engineer holding 63 patents in an array of industries, with an entrepreneurial spirit and a dream of helping patients with heart disease. His fascination with healing the heart was sparked in his teens, when he suffered two bouts of rheumatic fever, which can scar heart valves and eventually cause the heart to fail.
With a background in hydraulics and fuel pump operations, Edwards believed the human heart could be mechanized. He presented the concept to Dr. Albert Starr, a young surgeon at the University of Oregon Medical School, who thought the idea was too complex. Instead, Starr encouraged Edwards to focus first on developing an artificial heart valve, for which there was an immediate need.
After just two years, the first Starr-Edwards mitral valve was designed, developed, tested, and successfully placed in a patient. Newspapers around the world reported on what they termed a “miraculous” heart surgery.
From there, the company built an impressive pedigree for R&D in heart devices and minimally-invasive cardiovascular procedures. In 1966, Edwards Laboratories was purchased by American Hospital Supply Corporation and became American Edwards Laboratories. Then, in 1985, American Edwards was acquired by Baxter International. In early 2000, the company was spun-off as an independent, publicly-held corporation and began trading on the NYSE under the symbol EW.
Bear of the Day:
I last wrote about DaVita HealthCare Partners (DVA) as the Bear of the Day in mid-August when shares were trading above $68.
I wanted to revisit this story now because while we don't have any upward EPS estimate revisions to get the stock out of the Zacks Rank cellar, we did get a ratings upgrade from a respected firm that may soon mark the beginning of a turnaround for this important business.
Before I share details of that upgrade news, let's recap what has happened. DVA became a Zacks #4 Rank Sell in mid-July as analysts began lowering estimates before the company's Q2 report.
On August 8 the company delivered a 3% EPS beat but disappointed with lowered guidance for the year due to difficulties with a recent acquisition.
Since the earnings report, shares tumbled 13% up to August 16, the date of my first article, as most analysts have moved their estimates down again. Then from August 17 on, DVA dropped further but found support near $63, just above the 52-week lows of February at $61.36.
The Business of Dialysis
DaVita HealthCare Partners is the second-largest US provider of dialysis services to patients with chronic kidney failure and end stage renal disease. They serve roughly 180,000 patients through a network of 2,179 owned and managed dialysis facilities.
The company offers outpatient, home-based, and hospital inpatient hemodialysis services, ESRD laboratory services and provides management and administrative services to outpatient dialysis centers.
DaVita had revenues of $13.78 billion in 2015 and trailing 12-month (TTM) sales are at $14.36 billion as of June 30. DaVita HealthCare Partners Inc., formerly known as DaVita Inc., is headquartered in Denver, Colorado. With the acquisition of HealthCare Partners (HCP), the company became the largest operator of medical groups and physician networks in the US.
The Quarter Analysts Saw Coming... Mostly
Total revenue increased 8.8% year over year to approximately $3.72 billion and narrowly surpassed the Zacks Consensus Estimate by 1.2%. The year-over-year improvement was mainly attributable to a rise in patient service revenues.
Analysts knew that the HealthCare Partners acquisition was not going according to management's plans. That's why they were lowering estimates in July. But they weren't expecting a $70 million drop in segment guidance.
Here's how analysts at Raymond James broke down the news...
Drivers behind HCP’s lowered 2016 guidance include: 1) fee for service revenue growth of 3% vs. management 6% target, 2) an overestimation of Medicare Advantage reconciliation payments; 3) Medicare Advantage mentorship growth lower than expected and; 4) an acceleration in the re-branding of HCP to the DaVita Medical Group - $5/$10 million more than expected.
And here was the fallout for EPS estimates...
In the last 30 days, the 2016 full-year consensus fell from $3.95 to $3.77, representing negative annual growth of -1.7%.
2017 consensus profit projections dropped from $4.42 to $4.18, for 11% growth if all goes well.
The Upgrade from RJ
On September 20, analysts at Raymond James talked again about concerns in the market over DaVita's exposure to the ACA exchanges, noting that as the dust settled the risks appeared to be lower than they initially estimated in August.
And finding shares attractively valued after the sell-off, they felt compelled to move their rating on DVA shares from Market Perform to Outperform. They also issued a new $75 price target.
DaVita is a strong business and clear leader in its industry. But until the estimates picture turns around, it's probably best to stay on the sidelines. If the move by this investment bank becomes a new trend, and estimates head back up, then the turnaround could be in motion.
The Zacks Rank warned you in July before the drop and it will let you know when it's safe again.
2 Momentous Healthcare Stocks to Buy Now
Finding companies with the criteria you want isn’t always easy. You could spend hours searching ticker after ticker, only to find companies which aren’t worthy of your hard earned cash. An easier way to navigate through this is by using high quality stock screeners . Screening helps investors narrow down companies to invest in based on their ability to meet every criteria selected. Any company who misses even one of the criteria requirements will be filtered out.
This lets one easily choose ideal metrics. Screens are effective because they sift out bad stocks and only keep the cream of the crop in. It isn’t always easy to create an effective screen. Our Zacks Premium Screens have helped with this, bringing profits to many investors over time. Our predefined criteria are chosen carefully to capture special kinds of companies.
Today, we’ve dug up two healthcare stocks using one of our premium screens known as “Zacks #1 Rank Uptrends”. Some of the metrics of this screen requires a stock to have an average daily trading volume of at least 100,000 shares over the last 20 days, a price change greater than 10% over the last 12 weeks, and a positive price change over the last week. We added an additional metric which allowed us to screen for stocks from the healthcare sector. Without any further ado, let’s take a look at what our modified premium screen has found for us today.
Corcept Therapeutics Inc-(CORT - Analyst Report)
Corcept Therapeutics is focused on developing and commercializing drugs which treat severe metabolic, psychiatric, and oncologic disorders. CORT is build around treating conditions that are associated with the steroid hormone known as cortisol. CORT is a Zacks Rank #1 (Strong Buy) and it has a market cap of $659 million.
Corcept has multiple drugs which are progressing through trial phases so that they can receive FDA approval. The company has one approved drug on the market known as Korlym. Korlym was made for treating hyperglycemia associated with Cushing’s syndrome, a rare but debilitating endocrine disorder.
The company reported results from its second quarter in early August. Over the quarter, revenues came in at $19.7 million, picking up by 65% compared to Q2 of 2015. The company is bullish on seeing further growth in sales from Korlym, and it has reiterated its 2016 sales guidance of $76-$81 million.
Over the last 12 weeks, Corcept’s share price has grown by about 12%, and over the last week alone, the stock has picked up about 5%. CORT has an “A” for Growth in our Style Scores. For this fiscal year, EPS and sales are forecasted to grow by 267% and 59% respectively. The pharmaceutical company has done well to surpass our earnings expectations over each of the last four quarters, and it is expected to yield a positive EPS of $0.05 this year, according to our consensus estimate.
CORCEPT THERAPT Revenue (Quarterly) | CORCEPT THERAPT Quote
CryoLife Inc-(CRY - Snapshot Report)
CryoLife develops and sells implantable living human tissues for use in cardiovascular, vascular, and orthopedic surgeries across the US, Canada, and Europe. The firm has multiple products which are approved for marketing in the US and abroad. CryoLife is a Zacks Rank #1 (Strong Buy) and it has a market cap of $609 million.
CryoLife has a range of products which include surgical adhesives, heart valves, grafts, and more. The company’s adhesive products (BioGlue and BioFoam) accounted for about two thirds of quarterly sales. Sales from these two products have increased, but their dominating presence in CryoLife’s portfolio has decreased, thanks to the company’s acquisition of On-X Technologies. On-X’s artificial heart valve helped in boosting the company’s overall quarterly revenue by $9.5 million. In the company’s Q2 quarterly earnings release, sales grew by about 33% compared to the same quarter last year. Sales came in at $47.1 million for the quarter.
CryoLife’s stock has been very momentous over the last three months. Shares have climbed 48% higher since CRY released its Q2 earnings results on the 25 th of July. In the last week alone, shares have been trending upwards as well, pushing up 4% higher. Two months ago, our current year EPS consensus estimate forecasted earnings of $0.21 per share. Now, our consensus for this year estimates EPS of $0.34.
CRYOLIFE INC Revenue (Quarterly) | CRYOLIFE INC Quote
One magical screening ingredient which can’t be overlooked is a Zacks Rank #2 (Buy) or better. The rank helps to find companies which look like dependable earnings candidates. In addition to this great metric, the Zacks Premium Screenshelp you to add other criteria to find the most superior investment choices. While this article outlined potential candidates from one screen, the Zacks Premium service gives you access to the “ Zacks #1 Rank Uptrends ” and 45 other premium screens designed to give you superior investment returns.
To use Zacks Premium Screens to find more stock picks based on criteria that’s most important to you— plus, gain access to the Zacks Rank for your stocks, mutual funds and ETFs; Zacks Style Scores, Equity Research Reports; Focus List portfolio of 50-longer-term stocks and more— start your 30-day free trial to Zacks Premium.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Get today’s Zacks #1 Stock of the Day with your free subscription to Profit from the Pros newsletter:
About the Bull and Bear of the Day
Every day, the analysts at Zacks Equity Research select two stocks that are likely to outperform (Bull) or underperform (Bear) the markets over the next 3-6 months.
About the Analyst Blog
Updated throughout every trading day, the Analyst Blog provides analysis from Zacks Equity Research about the latest news and events impacting stocks and the financial markets.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous analyst coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Click here to subscribe to this free newsletter today.
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Zacks Investment Research
800-767-3771 ext. 9339
Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer .
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.